Weeklt OHDSI Digest - 4May2020

MauraBeaton · May 4, 2020, 8:44pm

OHDSI MEETINGS THIS WEEK

OHDSI STATEMENT ON COVID-19: OHDSI is committed to doing what it can to support and inform the COVID-19 pandemic response, and will prioritize activities aligned to this effort. As we adjust to the current global situation, the OHDSI community will continue to have our regular Tuesday community calls, as well as our various working group calls. Understandably, some calls could be postponed or cancelled due to issues surrounding COVID-19, so we ask that you continuously check the OHDSI forums, weekly digest and social channels for updated information. OHDSI is a virtual community, so we are equipped to continue collaboration during this challenging time.

OMOP CDM Oncology WG - Genomic Subgroup Meeting - Tuesday at 9am ET
URL: https://us04web.zoom.us/j/412862164?pwd=NmpEWTdTQlB4N3VxT0tQRXdDWlg0dz09
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg

Gold Standard Phenotype Library WG - Tuesday at 11am ET
URL: https://gatech.webex.com/gatech/j.php?MTID=mdd4af3e9b84212fc7df3eb0150703df5
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:gold-library-wg

OHDSI Community Call - Tuesday at 12pm ET
Zoom Meeting URL: https://columbiacuimc.zoom.us/j/945377669
Meeting ID: 945 377 669
Password: ohdsi
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:ohdsi_community

Common Data Model & Vocabulary WG - Tuesday at 1pmET
Meeting URL: https://meet.lync.com/jnj-its/mblacke/V59RPVRY
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:cdm-wg

OMOP CDM Oncology WG - Outreach/Research Subgroup Meeting - Tuesday at 3pm ET
URL: https://www.ohdsi.org/web/wiki/doku.php?id=documentation:oncology:outreach_schedule
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg

Patient-Level Prediction & Population-Level Estimation WG (Eastern Hemisphere) - Wednesday at 4pm (Korea Time)
Meeting URL: https://meet.lync.com/jnj-its/mschuemi/9CKLLR7L
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:patient-level_prediction

Oncology WG - Development Subgroup Meeting - Wednesday at 10am ET
URL: https://www.ohdsi.org/web/wiki/doku.php?id=documentation:oncology:development_schedule
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg

OMOP CDM Oncology WG - CDM/Vocabulary Subgroup Meeting - Thursday at 10am ET
URL: https://us04web.zoom.us/j/755053125?pwd=V0dOZVVnY3RMRWgxMVVGTDdVbnA1UT09
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg

Patient-Level Prediction & Population-Level Estimation WG (Western Hemisphere) - Thursday at 12pm ET
Meeting URL: https://meet.lync.com/jnj-its/mschuemi/KF143769
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:patient-level_prediction

China WG - Postponed to next Friday at 10am ET
Wiki: https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:china-wg

You can find a full list of upcoming OHDSI meetings here: https://docs.google.com/document/d/1X0oa9R-V8cwpF1WQZDJOqcXZguPKRiCZ6XrQ2zXMiuQ/edit

ANNOUNCEMENTS

New Teleconferencing Details for OHDSI Community Calls - Our weekly OHDSI community calls, which take place every Tuesday at noon will no longer be hosted via webex. For the time being, these calls will be hosted via Zoom. The details to join are:
Zoom Meeting URL: https://columbiacuimc.zoom.us/j/945377669
Meeting ID: 945 377 669

Women of OHDSI mentorship sessions - The Women of OHDSI will be holding ad hoc mentorship meetings, hosted by experts within a variety of areas. These meetings will have the aim of providing a forum for attendees to ask questions and seek guidance. Each meeting will be structured around a given topic, either focused on a specific technical area (ex. how to write a patient-level prediction protocol) or on general career development (ex. improving soft skills). The meetings may include a short presentation on the topic, but will primarily be designed for attendees to ask questions. To help us organize the meetings, please fill in this googleform and outline areas where you feel you could use more support: https://docs.google.com/forms/d/e/1FAIpQLSdXCGVaNZzhqAoVkWXMQOw0jypD6cMuRo658DgpxrkdC7WrBg/viewform

OHDSI F2F & 2020 US Symposium To do our part in reducing the spread of COVID-19 we have decided not to hold a F2F meeting this summer. However, planning for the 2020 U.S. Symposium, which will take place October 18-21st, is underway, and we will be sharing details when they become available.

COVID-19 Virtual Study-a-thon - To contribute to the COVID-19 response, the OHDSI community hosted a virtual study-a-thon on March 26-29th. For videos from this event, check out this forum post: FINAL GLOBAL UPDATE: #OHDSICOVID19 Study-A-Thon (video link posted)
And keep up-to-date on all post study-a-thon activities here: https://www.ohdsi.org/covid-19-updates/

I went to a general store but they wouldn’t let me buy anything specific.
Steven Wright

COMMUNITY PUBLICATIONS

Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.

ncbi.nlm.nih.gov

Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.

Z Yuan, F DeFalco, L Wang, L Hester, J Weaver, JN Swerdel, A Freedman, P Ryan, M Schuemie, R Qiu, J Yee, G Meininger, JA Berlin and N Rosenthal, Current medical research and opinion, Apr 25 2020

Objective: Observational evidence suggests that patients with type 2 diabetes mellitus (T2DM) are at increased risk for acute pancreatitis (AP) versus those without T2DM. A small number of AP events were reported in clinical trials of the sodium glucose co-transporter 2 inhibitor canagliflozin, though no imbalances were observed between treatment groups. This observational study evaluated risk of AP among new users of canagliflozin compared with new users of six classes of other antihyperglycemic agents (AHAs). Methods: Three US claims databases were analyzed based on a prespecified protocol approved by the European Medicines Agency. Propensity score adjustment controlled for imbalances in baseline covariates. Cox regression models estimated the hazard ratio of AP with canagliflozin compared with other AHAs using on-treatment (primary) and intent-to-treat approaches. Sensitivity analyses assessed robustness of findings. Results: Across the three databases, there were between 12,023-80,986 new users of canagliflozin; the unadjusted incidence rates of AP (per 1000 person-years) were between 1.5-2.2 for canagliflozin and 1.1-6.6 for other AHAs. The risk of AP was generally similar for new users of canagliflozin compared with new users of glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sulfonylureas, thiazolidinediones, insulin, and other AHAs, with no consistent between-treatment differences observed across databases. Intent-to-treat and sensitivity analysis findings were qualitatively consistent with on-treatment findings. Conclusions: In this large observational study, incidence rates of AP in patients with T2DM treated with canagliflozin or other AHAs were generally similar, with no evidence suggesting that canagliflozin is associated with increased risk of AP compared with other AHAs.

Medication Use for ADHD and the Risk of Driving Citations and Crashes Among Teenage Drivers: A Population-Based Cohort Study.

ncbi.nlm.nih.gov

Medication Use for ADHD and the Risk of Driving Citations and Crashes Among Teenage Drivers: A Population-Based Cohort Study.

AG Winterstein, Y Li, T Gerhard, S Linden and JJ Shuster, Journal of attention disorders, Apr 26 2020

Objectives: To evaluate the real-world effectiveness of ADHD medications on adverse driving outcomes in teenage drivers with ADHD. Method: We retrospectively followed 15- to 20-year-old ADHD patients with valid driver's license to compare the risk for crashes and citations between periods with and without ADHD medication use, using Florida Medicaid records linked to Department of Motor Vehicles data from 1999 to 2004. Patient-level demographic, clinical, and driver licensing characteristics as well as county-level crash and traffic statistics were adjusted in Cox models. Results: A total of 2,049 patients had 67 crashes and 319 citations. Adjusted hazard ratios comparing ADHD medication use versus no use were 1.22 (95% confidence interval [CI] = [0.66, 1.90]) and 0.89 (95% CI = [0.69, 1.13]) for crashes and citations, respectively. Conclusion: Our study showed no evidence that ADHD medication use was associated with a reduced risk of adverse driving outcomes among teenage drivers enrolled in Medicaid programs. Limitations in interpreting this finding are presented.